ncers."
The report's co-authors include researchers from Chester Beatty Laboratories,
London; the Sanger Centre, Cambs, U.K.; ICRF Clare Hall Laboratories, Potters
Bar, U.K.; the ICRF Genetic Epidemiology Laboratory, Leeds, U.K.; the University
of Cambridge and the CRC Human Cancer Genetics Research Group, Cambridge;
the University Hospital of Iceland, Reykjavik; Duke; the National Institute
of Environmental Health Sciences, Research Triangle Park, N.C.; Leiden
University, the Netherlands; Creighton University School of Medicine, Omaha,
Neb.; the International Agency for Research on Cancer, Lyon Cedex, France;
and McGill University, Montreal.
Funding for the project came from the Cancer Research Campaign, BREAKTHROUGH
Breast Cancer Charity and the Jean Rook Appeal, the Institute of Cancer
Research, the Wellcome Trust, the Medical Research Council, the Imperial
Cancer Research Fund, the U.S. Army, Duke University's Specialized Program
of Research Excellence in Breast Cancer, the National Cancer Institute,
the Icelandic Cancer Research Fund, the Nordic Cancer Union, the Dutch Cancer
Society, the Cancer Research Society, the Canadian Breast Cancer Foundation,
Ontario Chapter, the Fonds de las recherche en Sante du Quebec, the Canadian
Genetic Diseases Network and the Ligue Nationale Contre le Cancer.
'"/>
Contact: David Rice
rice0014@mc.duke.edu
Duke University
29-Apr-1996
Page: 1 2 3 4 Related biology news :1.
Second call for proposals for the European Young Investigator Award2.
Second generation targeted antibodies - Its all in the binding3.
Secondary complications and restoration of function in SCI4.
Second EMBO International Practical Workshop for Science Teachers5.
NTP-CERHR announces the Second Phthalates Expert Panel Meeting to be held December 15-17, 19996.
In Logged Forests, Hunting of Wildlife Becomes Deadly Second Harvest7.
Iron Supplemented Formula Milk Should Be Free For Inner City Children Into Their Second Year Of Life8.
Oregon Scientists Discover A Second Blood-Brain Barrier; Important Finding For Patients With Brain Cancers And Neurological Disorders9.
When One Gene Has Two Roles, Its Second Function May Be Missed10.
Phase III Results Suggest Potent Antiviral Activity For Vertex And Glaxo Wellcomes Second-Generation HIV Protease Inhibitor Agenerase TM11.
The Second Visible Human Project Conference